Keros Therapeutics Inc KROS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/21/24 EDT
50.43UNCH (UNCH)
Volume
8,799
Close
50.43UNCH (UNCH)
Volume
262,394
52 week range
27.02 - 73.00
Loading...
  • Open52.22
  • Day High52.69
  • Day Low50.07
  • Prev Close50.43
  • 52 Week High73.00
  • 52 Week High Date02/29/24
  • 52 Week Low27.02
  • 52 Week Low Date10/26/23

Key Stats

  • Market Cap1.82B
  • Shares Out36.08M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change26.84

KEY STATS

  • Open52.22
  • Day High52.69
  • Day Low50.07
  • Prev Close50.43
  • 52 Week High73.00
  • 52 Week High Date02/29/24
  • 52 Week Low27.02
  • 52 Week Low Date10/26/23
  • Market Cap1.82B
  • Shares Out36.08M
  • 10 Day Average Volume0.25M
  • Dividend-
  • Dividend Yield-
  • Beta1.27
  • YTD % Change26.84

RATIOS/PROFITABILITY

  • EPS (TTM)-5.14
  • P/E (TTM)-9.81
  • Fwd P/E (NTM)-10.12
  • EBITDA (TTM)-178.63M
  • ROE (TTM)-39.63%
  • Revenue (TTM)233,999.997
  • Gross Margin (TTM)-
  • Net Margin (TTM)-68,505.13%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/05/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Keros Therapeutics Inc

 

Profile

MORE
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic...
Ran Nussbaum
Independent Chairman of the Board
Jasbir Seehra Ph.D.
Chief Executive Officer, Director
Christopher Rovaldi
Chief Operating Officer
Keith Regnante
Chief Financial Officer
Address
1050 Waltham Street, Suite 302
Lexington, MA
02421
United States

Top Peers

SYMBOLLASTCHG%CHG
SANA
Sana Biotechnology Inc
8.30UNCHUNCH
FUSN
Fusion Pharmaceuticals Inc
21.49UNCHUNCH
INBX
Inhibrx Inc
34.24UNCHUNCH
SNDX
Syndax Pharmaceuticals Inc
20.66UNCHUNCH
RCKT
Rocket Pharmaceuticals Inc
22.33UNCHUNCH